Physician profile
Deetta Debault
NPI 1477960888
$14,327.84
in general payments reported to CMS, 2019-2025
63 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 90% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,534 · 2022: $3,485 · 2023: $3,206 · 2024: $1,649 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,291 · Education: $17.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,291.28 |
| Education | $17.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,371.10 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,182.67 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,006.27 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $989.50 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $828.83 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $578.31 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $556.75 | 2021-2024 | |
| Amgen INC. | $541.31 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $517.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $480.64 | 2021-2024 | |
| Axsome Therapeutics, INC. | $464.80 | 2023-2025 | Auvelity |
| Antares Pharma, INC. | $439.61 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $367.93 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $352.93 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.93 | 2022-2025 | Caplyta |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deetta Debault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.